Table 1.
Patient characteristics at baseline.
| Characteristic | No (%), n=137 |
|---|---|
| Age at diagnosis (years), median (range) | 48 (27-74) |
| Age at diagnosis (years) | |
| ≤50 | 93 (67.88) |
| >50 | 44 (32.12) |
| Pathological type | |
| Invasive ductal carcinoma | 133 (97.08) |
| Others | 4 (2.92) |
| Hormone receptor status | |
| Positive | 73 (53.28) |
| Negative | 64 (46.72) |
| Ki67 (%) | |
| <30 | 62 (45.26) |
| ≥30 | 75 (54.74) |
| Extent of disease at diagnosis | |
| Stage IV at first diagnosis | 34 (24.82) |
| Recurrence or metastasis | 103 (75.18) |
| Metastatic sites | |
| Bone | 58 (42.34) |
| Liver | 49 (35.77) |
| Lung | 55 (40.15) |
| Brain | 38 (27.74) |
| Lymph nodes | 62 (45.26) |
| Local recurrence | 31 (22.63) |
| Contralateral breast | 9 (6.57) |
| No. of metastatic sites | |
| 1 | 39 (28.47) |
| 2 | 45 (32.85) |
| 3 | 27 (19.71) |
| ≥4 | 26 (18.98) |
| Visceral metastases | |
| Yes | 107 (78.10) |
| No | 30 (21.90) |
| Trastuzumab sensitivity | |
| sensitivity | 92 (67.15) |
| insensitivity | 45 (32.85) |
| Prior HER2-targeted therapy | |
| Trastuzumab | 124 (90.51) |
| Pertuzumab | 23 (16.79) |
| Lapatinib | 19 (13.87) |
| T-DM1 | 4 (2.92) |
| Non-used | 13 (9.49) |